Moderna Inc
1MRNA
Company Profile
Business description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Contact
325 Binney Street
CambridgeMA02139
USAT: +1 617 714-6500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
5,800
Stocks News & Analysis
stocks
Amazon earnings: Guidance for $200 billion in capital expenditure in 2026 overshadows good results
We think Amazon stock is moderately undervalued.
stocks
Apple earnings: Impressive Q4 lifts stock, but is it a long-term growth play?
We’ve raised our fair value estimate of Apple stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,133.00 | 67.10 | 0.74% |
| CAC 40 | 8,273.84 | 35.67 | 0.43% |
| DAX 40 | 24,721.46 | 230.40 | 0.94% |
| Dow JONES (US) | 50,115.67 | 1,206.95 | 2.47% |
| FTSE 100 | 10,369.75 | 60.53 | 0.59% |
| HKSE | 27,006.42 | 446.47 | 1.68% |
| NASDAQ | 23,031.21 | 490.63 | 2.18% |
| Nikkei 225 | 56,663.85 | 2,410.17 | 4.44% |
| NZX 50 Index | 13,448.53 | 4.51 | 0.03% |
| S&P 500 | 6,932.30 | 133.90 | 1.97% |
| S&P/ASX 200 | 8,873.80 | 62.90 | 0.71% |
| SSE Composite Index | 4,113.58 | 48.00 | 1.18% |